Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:2992 |
Name | prostate neuroendocrine neoplasm |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate neuroendocrine neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
KIT positive | Imatinib | prostate neuroendocrine neoplasm | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01799278 | Phase II | Alisertib | A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer | Completed | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Recruiting | ITA | FRA | ESP | 2 |
NCT03582475 | Phase I | Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | Recruiting | USA | 0 |
NCT03837353 | Phase Ib/II | DKN-01 DKN-01 + Docetaxel | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | Recruiting | USA | 0 |
NCT03910660 | Phase Ib/II | Pembrolizumab + Talabostat mesylate | A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer | Recruiting | USA | 1 |
NCT04090775 | Phase II | Cyclophosphamide + Ipilimumab + Nivolumab | A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma | Terminated | USA | 0 |
NCT04179864 | Phase I | Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat | A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ESP | BEL | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04702737 | Phase I | AMG 757 | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Recruiting | USA | FRA | ESP | BEL | AUT | 4 |
NCT04709276 | Phase II | Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) | Recruiting | USA | 0 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Recruiting | USA | 0 |